


AMENDMENTS TO THE CLAIMS:


This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF THE CLAIMS:


1-23. (cancelled)

24. (currently amended) A compound of the following general formula (I):






wherein R_1 and R_2 are fatty acyl groups selected from the group consisting of:



wherein m is 14 or 16 and n is an integer from 2 to 10.

25. (cancelled)

26. (currently amended) The compound according to claim 24, wherein R_1 ~~and R_2 are selected from the group consisting of~~ is palmitic acyl and R_2 is stearic acyl, and the compound ~~having~~ has the formula:




27. (previously presented) The compound according to claim 24, wherein at least one of R_1 and R_2 represents a hydroxyphthioceranoic acyl group.

28. (previously presented) The compound according to claim 24, wherein R_1 or R_2 represents a hydroxyphthioceranoic acyl group.

29. (currently amended) The compound according to claim 24, wherein:


- R_1 represents a hydroxyphthioceranoic acyl group, and R_2 represents a palmitic acyl group or a stearic acyl group, ~~namely compounds of~~ and the compound has the following formula (II):



[[II]] II

wherein p is 14 or 16, m is 14 or 16 and n is an integer from 2 to 10, or


- R₂ represents a hydroxyphthioceranoic acyl group, and R₁ represents a palmitic acyl group or a stearic acyl group, ~~namely compounds of~~ and the compound has the following formula (III):



[[III]] III

wherein p is 14 or 16, m is 14 or 16 and n is an integer from 2 to 10.

30. (currently amended) The compound according to claim 24, wherein the compound is of the following formula II,



[[II]] II

wherein the compound is selected from the group consisting of:

- n = 2, m = 14 and p = 14 (II.1) ;
- n = 2, m = 14 and p = 16 (II.2) ;
- n = 2, m = 16 and p = 14 (II.3) ;
- n = 2, m = 16 and p = 16 (II.4) ;
- n = 3, m = 14 and p = 14 (II.5) ;
- n = 3, m = 14 and p = 16 (II.6) ;
- n = 3, m = 16 and p = 14 (II.7) ;
- n = 3, m = 16 and p = 16 (II.8) ;
- n = 4, m = 14 and p = 14 (II.9) ;
- n = 4, m = 14 and p = 16 (II.10) ;
- n = 4, m = 16 and p = 14 (II.11) ;
- n = 4, m = 16 and p = 16 (II.12) ;
- n = 5, m = 14 and p = 14 (II.13) ;
- n = 5, m = 14 and p = 16 (II.14) ;
- n = 5, m = 16 and p = 14 (II.15) ;
- n = 5, m = 16 and p = 16 (II.16) ;

- $n = 6, m = 14$ and $p = 14$ (II.17) ;
- $n = 6, m = 14$ and $p = 16$ (II.18) ;
- $n = 6, m = 16$ and $p = 14$ (II.19) ;
- $n = 6, m = 16$ and $p = 16$ (II.20) ;


- $n = 7, m = 14$ and $p = 14$ (II.21) ;
- $n = 7, m = 14$ and $p = 16$ (II.22) ;
- $n = 7, m = 16$ and $p = 14$ (II.23) ;
- $n = 7, m = 16$ and $p = 16$ (II.24) ;

- $n = 8, m = 14$ and $p = 14$ (II.25) ;
- $n = 8, m = 14$ and $p = 16$ (II.26) ;
- $n = 8, m = 16$ and $p = 14$ (II.27) ;
- $n = 8, m = 16$ and $p = 16$ (II.28) ;

- $n = 9, m = 14$ and $p = 14$ (II.29) ;
- $n = 9, m = 14$ and $p = 16$ (II.30) ;
- $n = 9, m = 16$ and $p = 14$ (II.31) ;
- $n = 9, m = 16$ and $p = 16$ (II.32) ;

- $n = 10, m = 14$ and $p = 14$ (II.33) ;
- $n = 10, m = 14$ and $p = 16$ (II.34) ;
- $n = 10, m = 16$ and $p = 14$ (II.35) ; and
- $n = 10, m = 16$ and $p = 16$ (II.36) ;

or of the following formula III,



[[III]] III

wherein the compound is selected from the group consisting of

- $n = 2$, $m = 14$ and $p = 14$ (III.1) ;
- $n = 2$, $m = 14$ and $p = 16$ (III.2) ;
- $n = 2$, $m = 16$ and $p = 14$ (III.3) ;
- $n = 2$, $m = 16$ and $p = 16$ (III.4) ;

- $n = 3$, $m = 14$ and $p = 14$ (III.5) ;
- $n = 3$, $m = 14$ and $p = 16$ (III.6) ;
- $n = 3$, $m = 16$ and $p = 14$ (III.7) ;
- $n = 3$, $m = 16$ and $p = 16$ (III.8) ;

- $n = 4$, $m = 14$ and $p = 14$ (III.9) ;
- $n = 4$, $m = 14$ and $p = 16$ (III.10) ;
- $n = 4$, $m = 16$ and $p = 14$ (III.11) ;
- $n = 4$, $m = 16$ and $p = 16$ (III.12) ;

- $n = 5$, $m = 14$ and $p = 14$ (III.13) ;
- $n = 5$, $m = 14$ and $p = 16$ (III.14) ;
- $n = 5$, $m = 16$ and $p = 14$ (III.15) ;
- $n = 5$, $m = 16$ and $p = 16$ (III.16) ;

- $n = 6$, $m = 14$ and $p = 14$ (III.17) ;
- $n = 6$, $m = 14$ and $p = 16$ (III.18) ;

- $n = 6, m = 16$ and $p = 14$ (III.19) ;
- $n = 6, m = 16$ and $p = 16$ (III.20) ;


- $n = 7, m = 14$ and $p = 14$ (III.21) ;
- $n = 7, m = 14$ and $p = 16$ (III.22) ;
- $n = 7, m = 16$ and $p = 14$ (III.23) ;
- $n = 7, m = 16$ and $p = 16$ (III.24) ;

- $n = 8, m = 14$ and $p = 14$ (III.25) ;
- $n = 8, m = 14$ and $p = 16$ (III.26) ;
- $n = 8, m = 16$ and $p = 14$ (III.27) ;
- $n = 8, m = 16$ and $p = 16$ (III.28) ;


- $n = 9, m = 14$ and $p = 14$ (III.29) ;
- $n = 9, m = 14$ and $p = 16$ (III.30) ;
- $n = 9, m = 16$ and $p = 14$ (III.31) ;
- $n = 9, m = 16$ and $p = 16$ (III.32) ;

- $n = 10, m = 14$ and $p = 14$ (III.33) ;
- $n = 10, m = 14$ and $p = 16$ (III.34) ;
- $n = 10, m = 16$ and $p = 14$ (III.35) ; and
- $n = 10, m = 16$ and $p = 16$ (III.36).


31. (currently amended) ~~Compounds~~ The compound
according to claim 24, ~~of following formulae~~ having a formula
selected from the group consisting of:




[[III.21]] III.21,




[[II.21]] II.21,



[[III.2]] III.2,



[[III.23]] III.23, and




[[II.23]] II.23 .

32. (currently amended) A composition comprising a mixture of at least two different compounds of formula I ~~such as~~ defined in according to claim 24, wherein the at least two different compounds of formula (I) have different definitions for at least one of R_1 and R_2 .

33. (currently amended) [[A]] The composition according to claim 32, ~~characterized in that it comprises a~~ wherein the mixture ~~of compounds~~ of at least two different compounds is selected from [[the]]


(i) compounds of following according to formula (II):



[[II]] II

wherein p is 14 or 16, m is 14 or 16 and n is an integer from 2 to 10, and the compounds differ by at least one of p, m or n or


(ii) ~~from the compounds of following~~ according to formula (III):




[[III]] III

wherein p is 14 or 16, m is 14 or 16 and n is an integer from 2 to 10, and the compounds differ by at least one of p, m or n.


34. (currently amended) [[A]] The composition according to claim 32, characterized in that it comprises a wherein the mixture of compounds selected from at least two different compounds is the following compounds:




[[III.21]] III.21




[[II.21]] II.21




[[III.22]] III.22



[[II.22] II.22



[[III.23] III.23, and



[[II.23] II.23.

35. (currently amended) The composition according to claim 34, wherein the compounds represent from about 20% to about 100%, ~~more particularly about 30%,~~ of the total amount of compounds of formula I of said composition.

36. (previously presented) A pharmaceutical composition comprising at least one compound of claim 24, in association with a pharmaceutically acceptable vehicle.

37. (previously presented) The pharmaceutical composition according to claim 36, characterized in that it is presented in a form intended for administration by oral or injectable route.

38. (currently amended) ~~[[A]]~~ The pharmaceutical composition according to claim 36, characterized in that it comprises further comprising one or more other products useful for the treatment or the prophylaxis of tuberculosis, such as BCG or mycobacterial proteins selected from the group consisting of cytokines, DNA fragments encoding *M. tuberculosis* antigens, live *M. tuberculosis* deletion mutants and live recombinant Bacillus of Calmette and Gerinor.

39. (currently amended) A product comprising:
- at least one compound ~~[[of]]~~ according to claim 24,
- and at least one other product useful for the treatment or the prophylaxis of tuberculosis selected from the group consisting of cytokines, DNA fragments encoding *M. tuberculosis* antigens, live *M. tuberculosis* deletion mutants and live recombinant Bacillus of Calmette and Gerinor,

as a combined preparation for simultaneous, separate or sequential use in the treatment or the prophylaxis of tuberculosis.

40. (currently amended) A method for the treatment or the prophylaxis of tuberculosis, comprising the administration of

a therapeutically effective amount to a patient of at least one compound [[of]] according to claim 24.

41. (currently amended) A method of activating immune reaction, comprising the administration of a therapeutically effective amount to a patient of at least one compound[[of]] according to claim 24.

42. (currently amended) A method of inducing the activation of T lymphocytes, comprising the administration of a therapeutically effective amount to a patient of at least one compound [[of]] according to claim 24.

43. (currently amended) A method of inducing the production of IFN- γ , TNF- α , IL-4 or granulysin, comprising the administration of a therapeutically effective amount to a patient of at least one compound [[of]] according to claim 24.

44-45. (cancelled)

46. (withdrawn-currently amended) A process for screening ~~products, such as sulfoglycolipids~~ for the compound according to claim 24 extracted from *Mycobacterium tuberculosis*, ~~characterised in that said process comprises~~ comprising the following stages:

- contacting dendritic cells loaded with the ~~product~~ compound to screen, ~~notably sulfoglycolipids extracted from *Mycobacterium tuberculosis*,~~ with T cell clones ~~according to claim 45,~~ and
- detecting a molecule selected from the group comprising consisting of IFN- γ , TNF- α , granulysin and IL-4, released by the T cell clones,

wherein the T cell clones are generated by a process comprising the steps of:

- incubating antigen presenting cells (APCs) with a *Mycobacterium tuberculosis* envelope preparation substantially devoid of proteins, to obtain non-protein envelope antigen loaded APCs,
- contacting peripheral blood mononuclear cells with the envelope antigen loaded APCs to obtain proliferating T cells, and
- cloning proliferating T cells by limiting dilution and selecting the clones releasing a molecule selected from the group consisting of IFN- γ , TNF- α , granulysin and IL-4 when contacted by envelope antigen loaded APCs to obtain T cell clones.

47. (currently amended) A process for the extraction of ~~compounds~~ the compound of claim 24, from *Mycobacterium tuberculosis*, characterized in that said process comprises comprising the following stages:

- ~~treatment of~~ treating *M. tuberculosis* bacteria with a mixture of methanol and chloroform to obtain a chloroform/methanol extract,
- ~~concentration of~~ concentrating the chloroform/methanol extract followed by its partition between a chloroform phase and an aqueous phase,
- taking of the chloroform phase and evaporation of most of the chloroform, followed by ~~addition of~~ adding acetone thereto to obtain a precipitate and a soluble acetone phase,
- taking of the soluble acetone phase followed by concentration, and ~~application of~~ applying the concentrated soluble acetone phase on a silicic acid

column irrigated with mixtures of methanol and chloroform,

- ~~elution of~~ eluting a fraction from the above-mentioned silicic acid column by a mixture of chloroform and approximately 20% methanol,
- if necessary ~~purification of~~ purifying the fraction eluted from the silicic acid column to obtain different preparations respectively containing substantially only one compound.